Press release & events

From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.

In the era of immuno-oncology, it’s critical to unravel mechanisms of action underlying sensitivity or resistance to current immunotherapies in order to identify predictive biomarkers of response and then discover novel actionable therapeutic targets.

Back from the AACR 2022, it was a pleasure to take part in it and to converse about our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.

If you didn't get the chance to meet us and see our posters, or if you want to review them, you can directly download them from the form below.

We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there,  approach your research projects and introduce our service offerings. We will also presentsome scientific posters to highlight our latest innovative preclinical and translational research advances.

Drawing on our expertise in multiplexed-immunohistofluoresence (IHF) and immunohistochemistry (IHC) assays, we have already developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets. While bringing key answers to address specific questions, our capacities have recently been highlighted in new scientific publications of collaborative works with Institut Bergonié, which we are delighted to share thereafter.

Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed.

January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than €9.8M ($11.1M) to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).

Explicyte was pleased to participate to the AACR Virtual Annual Meeting, last week to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities / platforms that support drug discovery.

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.